934423-10-6 Usage
General Description
(R)-1-tert-butyl 3-methyl piperidine-1,3-dicarboxylate is a chemical compound that belongs to the class of piperidine derivatives. It is a chiral compound with a tert-butyl group and a methyl group attached to the piperidine ring, and two carboxylate groups attached to different carbon atoms of the piperidine ring. (R)-1-tert-butyl 3-methyl piperidine-1,3-dicarboxylate has potential applications in medicinal chemistry, particularly in the development of new drugs and pharmaceuticals. Its unique structure and chiral nature make it a valuable building block for the synthesis of novel molecules with biological activity. Additionally, the tert-butyl and methyl groups contribute to the compound's lipophilicity and steric hindrance, which can impact its pharmacokinetic properties in potential drug candidates. Overall, (R)-1-tert-butyl 3-methyl piperidine-1,3-dicarboxylate is a versatile chemical compound with potential applications in drug discovery and development.
Check Digit Verification of cas no
The CAS Registry Mumber 934423-10-6 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,3,4,4,2 and 3 respectively; the second part has 2 digits, 1 and 0 respectively.
Calculate Digit Verification of CAS Registry Number 934423-10:
(8*9)+(7*3)+(6*4)+(5*4)+(4*2)+(3*3)+(2*1)+(1*0)=156
156 % 10 = 6
So 934423-10-6 is a valid CAS Registry Number.
934423-10-6Relevant articles and documents
Diazabicyclo compounds and application thereof
-
Paragraph 0097; 0147-0149, (2020/06/09)
The invention belongs to the field of medical chemistry and, relates to diazabicyclo compounds and application thereof, and particularly provides compounds as shown in the formula (I) or isomers, pharmaceutically acceptable salts, solvates, crystals or pr
HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE
-
Page/Page column 303, (2009/02/10)
To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, -O-, or - CH2-; R1 represents a hydrogen atom or a C1-C6 alkyl group, and V represents any one group selected from among the following groups (1) to (3) : (1) -G1-, (2) -G2-N(R2) -G3-, and (3) a group represented by formula 2, wherein each of Z1 and Z2 represents a hydrogen atom or a C1-C6 alkyl group, Z3 represents a hydrogen or the like, Q represents -CH2-O- or the like, and Y represents a group represented by foumula 3, a salt thereof, or a solvate thereof.